Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exosomes: small vesicles with big roles in hepatocellular carcinoma

Wu Z., Zeng Q., Cao K., Sun Y.

Narrative Review on Face & Skin, published in Oncotarget (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Oncotarget (2016)
Reported sample size
—
Source database
Europe PMC
PMID
27463001
PMCID
PMC5312412
DOI
10.18632/oncotarget.10807
Citations
23

Abstract (original English)

Despite improvements in the diagnosis and treatment of hepatocellular carcinoma (HCC), the prognosis is still poor. Pioneering work has demonstrated a potential role for tumour cell-derived exosomes (TEXs) in HCC. TEXs can mediate immune responses, antigen presentation and intracellular communication by serving as vehicles for the transfer of proteins, viruses, lipids and RNA between cells. An improved understanding of the roles played by exosomes could lead to a powerful new strategy for preventing and treating HCC. In this review, we summarise current understanding on the topic. The literature points to two faces of TEXs in HCC: 1) They can promote invasion, metastasis, immune evasion and modulation and 2) they can act as diagnostic and prognostic biomarkers, and can be used in anti-cancer drug resistance and immunotherapy in the future.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Secretory VesiclesAnimalsHumansCarcinoma, HepatocellularLiver NeoplasmsNeoplasm MetastasisImmunotherapyTumor EscapeExosomesTumor Microenvironment

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research